Profile data is unavailable for this security.
About the company
Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
- Revenue in EUR (TTM)4.86m
- Net income in EUR-3.36m
- Incorporated2005
- Employees61.00
- LocationAbionyx Pharma SABat. D 33-43 Avenue Georges PompidouBALMA 31130FranceFRA
- Phone+33 562249706
- Fax+33 562190417
- Websitehttps://www.abionyx.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poxel SA | 1.98m | -35.09m | 12.27m | 22.00 | -- | -- | -- | 6.19 | -1.08 | -1.08 | 0.0591 | -1.27 | 0.1002 | -- | 5.09 | 90,045.45 | -177.50 | -52.39 | -- | -92.20 | 0.0505 | -- | -1,771.33 | -299.15 | -- | -1.39 | -- | -- | 193.92 | -49.84 | -11.76 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 2.53m | 1.09m | 13.70m | 27.00 | 12.34 | -- | 8.69 | 5.41 | 0.9967 | 0.9967 | 2.32 | -- | -- | -- | -- | 93,777.41 | -- | -3.53 | -- | -4.39 | 110.03 | 134.21 | 43.01 | -33.16 | -- | 12.90 | -- | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Predilife SA | 317.79k | -4.22m | 15.55m | 19.00 | -- | -- | -- | 48.92 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Phaxiam Therapeutics SA | 2.14m | -21.92m | 17.22m | 54.00 | -- | 0.6763 | -- | 8.04 | -3.46 | -3.46 | 0.3956 | 2.54 | 0.0409 | -- | 8.56 | 41,980.39 | -41.90 | -50.69 | -61.11 | -66.25 | -- | -- | -1,023.96 | -1,009.09 | -- | -70.91 | 0.4556 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Oncodesign Precision Medicine Opm SA | 468.73k | -7.78m | 18.46m | 19.00 | -- | 5.86 | -- | 39.39 | -0.449 | -0.449 | 0.0269 | 0.1733 | 0.0311 | -- | 0.4553 | 21,305.91 | -51.68 | -- | -85.27 | -- | 153.18 | -- | -1,660.23 | -- | -- | -360.87 | 0.715 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Nfl Biosciences SAS | 0.00 | -2.37m | 19.18m | 4.00 | -- | 5.51 | -- | -- | -0.2653 | -0.2653 | 0.00 | 0.3584 | 0.00 | -- | -- | 0.00 | -44.70 | -83.27 | -70.88 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -53.28 | -- | -- | -- |
| Valbiotis SA | 527.00k | -8.94m | 19.55m | 52.00 | -- | 1.16 | -- | 37.10 | -0.6571 | -0.6571 | 0.0373 | 1.07 | 0.0208 | 2.52 | 0.2447 | 10,134.62 | -35.21 | -32.92 | -46.61 | -46.36 | -511.95 | 53.15 | -1,697.15 | -418.87 | 4.54 | -91.62 | 0.266 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Fermentalg SA | 8.04m | -14.14m | 25.42m | 58.00 | -- | 0.6626 | -- | 3.16 | -0.2787 | -0.2787 | 0.1521 | 0.4452 | 0.1395 | 1.34 | 4.82 | 129,629.00 | -22.80 | -21.94 | -25.70 | -24.71 | 14.04 | 14.73 | -163.46 | -248.95 | 3.42 | -53.95 | 0.2639 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
| genOway SA | 21.42m | 1.26m | 34.78m | 128.00 | 26.14 | 1.84 | 9.28 | 1.62 | 0.1435 | 0.1435 | 2.45 | 2.04 | 0.6658 | 1.39 | 3.26 | 161,089.30 | 3.90 | 0.2166 | 5.40 | 0.3048 | 92.34 | 94.82 | 5.86 | 0.4177 | 1.81 | -- | 0.2639 | -- | 17.55 | 13.16 | 101.55 | 22.35 | -14.31 | -- |
| Gensight Biologics SA | 804.00k | -20.11m | 36.81m | 11.00 | -- | -- | -- | 45.79 | -0.3537 | -0.3537 | 0.0123 | -0.2402 | 0.0507 | -- | 21.73 | 50,250.00 | -126.79 | -79.44 | -- | -144.54 | -- | -- | -2,501.00 | -1,036.27 | -- | -1,250.38 | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Novacyt SA | 22.31m | -44.90m | 40.96m | 240.00 | -- | 0.4836 | -- | 1.84 | -0.6357 | -0.6405 | 0.3159 | 1.20 | 0.1603 | -3.66 | 1.02 | 82,619.26 | -32.27 | 10.94 | -38.44 | 14.49 | 153.78 | 61.98 | -201.27 | 17.64 | 3.82 | -23.91 | 0.1573 | -- | -44.97 | -0.9408 | -25.22 | -- | 2.09 | -- |
| Abionyx Pharma SA | 4.86m | -3.36m | 43.52m | 61.00 | -- | 4.25 | -- | 8.96 | -0.1063 | -0.1063 | 0.1548 | 0.2934 | 0.3316 | 21.80 | 6.05 | 80,264.46 | -22.93 | -18.82 | -33.15 | -28.87 | 19.19 | 14.32 | -69.15 | -128.54 | 2.22 | -114.07 | 0.2513 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
Data as of Nov 22 2024. Currency figures normalised to Abionyx Pharma SA's reporting currency: Euro EUR
0.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gestys SAas of 30 Aug 2024 | 9.00k | 0.03% |
Data from 30 Aug 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
